MDedge Psychcast

The case for long-acting injectables


 

Allowing patients with a first episode to experience a second is unacceptable, Henry A. Nasrallah, MD, editor in chief of Current Psychiatry, said in his interview with Lorenzo Norris, MD, editor in chief of MDedge Psychiatry.

“It’s not too late to use injectables after the first episode, but my God, why are we letting them lose so much tissue and have so much suffering, so much PTSD, so much stigma, so much poverty, so much incarceration that comes from having repetitive psychotic episodes and deteriorating?” Dr. Nasrallah asked. “We can prevent all of that by utilizing, exploiting those agents.”

Dr. Nasrallah serves as a consultant and on the advisory boards of several companies, including Acadia, Alkermes, Allergan, Boehringer-Ingelheim, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, and Teva. He also serves on the speakers bureaus of several companies. Dr. Norris has no disclosures.

Recommended Reading

Early trauma exposure tied to telomere shortening in men with schizophrenia
MDedge Psychiatry
Consanguineous parentage raises risk of mood disorders, psychoses in offspring
MDedge Psychiatry
MDedge Psychcast: Interview with Dr. Henry Nasrallah
MDedge Psychiatry
Targeting obesity could slow brain aging in psychosis
MDedge Psychiatry
Real-world data so far support pimavanserin trial results
MDedge Psychiatry
Treating psychosis in patients with HIV/AIDS
MDedge Psychiatry
Substance use linked to conversion to schizophrenia
MDedge Psychiatry
MDedge Daily News: Lupus is quietly killing young women
MDedge Psychiatry
Schizophrenia: Psychiatrists ‘can do much more’ for patients
MDedge Psychiatry
Tardive dyskinesia: Screening and management
MDedge Psychiatry